United States Influenza Vaccine Market PowerPoint PPT Presentations

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.

DPI Research has published a new research report titled “United States Influenza Vaccines Market Size, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2031 ” in its research database. The influenza vaccines market in the United States was valued at US$ 3,962 million in 2022 and is expected to reach US$ 8,347 million by 2031, registering a CAGR of 8.6% during the forecast period.

The average human life span has grown significantly primarily due to vaccination. Vaccines have transformed public health throughout the world, especially for children. In the United States, among the various diseases like Influenza, Rotavirus, Hepatitis (Hepatitis A and Hepatitis B), Polio, DTap, HIB, Pneumococcal conjugate, Varicella, MMR and HPV, influenza is the most common viral infection. Quadrivalent is the most common flu vaccines in the United States, which was licensed in the year 2012. According to Renub Research, United States Vaccine Market is poised to reach US$ 11.4 Billion by 2026.

The United States pediatric vaccines are expected to remain highly active in the future, fueled by the encouragement and financing from Governments and other health organizations. To know more : https://www.bharatbook.com/healthcare-market-research-reports-666201/united-states-pediatric-vaccines-immunization.html

Influenza Vaccines Market

Bharat Book Bureau provides the report; on “Global Influenza Vaccines Market”. (https://www.bharatbook.com/healthcare-market-research-reports-644661/global-influenza-vaccines-persons-vaccinated-brand-analysis.html) The report provides detailed analysis of Global Influenza Vaccines Market with respect to major segments such as type, structure and product, and comprehensive analysis of market dynamics including factors and opportunities is included in the report.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue million USD, market share and growth rate of Influenza Vaccines in these regions, from 2013 to 2025 forecast, covering North America Europe China Japan Southeast Asia India

Renub Research (http://www.renub.com/united-states-pediatric-vaccines-market-doses-immunization-vaccinated-cases-and-forecast-115-p.php) has announced the addition of the "United States Pediatric Vaccines Market, Doses, Immunization (Vaccinated), Cases & Forecast" report to its offering

Influenza Vaccine market, analyzes and researches the Influenza Vaccine development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like

Renub Research (http://www.renub.com/united-states-pediatric-vaccines-market-doses-immunization-vaccinated-cases-and-forecast-115-p.php) has announced the addition of the "United States Pediatric Vaccines Market, Doses, Immunization (Vaccinated), Cases & Forecast" report to its offering

iGATE Research (www.igateresearch.com) report titled Influenza Vaccines Market and Forecast - Global Analysis provides a comprehensive analysis of the fast-evolving influenza vaccines market. This 176 Page report contains 117 Figures and 8 Tables to present a clear picture of the influenza vaccines market landscape. The Influenza Vaccines Market have been analyzed from 4 viewpoints: 1. Influenza Vaccines Market, Persons Vaccinated and Forecast - Geographical Distribution (2011 - 2021) 2. Global - Influenza Vaccines Brand Sales and Forecast to 2021 3. Global Influenza Vaccines Market - Major Deals 4. Global Influenza Vaccines Market - Driving Factors and Challenges

United States Pediatric Vaccine market is likely to reach nearly US$ 10 Billion by 2024. Buy Now : http://www.dpiresearch.com/report-details.php?P_ID=118 Growth in US pediatric vaccine market can be attributed to factors such as increased disease awareness, growing public acceptance, increasing government focus on immunization programs and increased government funding for the vaccine development.

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022. For Sample Pages of the Report: http://www.dpiresearch.com/page_info.php?P_ID=50 Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.

In the Americas, United States captures majority of the influenza vaccines market share. Brazil is the second leading market for influenza vaccines with around XX% share in 2015. Canada and Mexico are the third and fourth leading market for influenza vaccines with XX% and XX% market share respectively in 2015. In the influenza vaccines brand sales segment, Sanofi's Fluzone holds the maximum share of the market being followed by Fluvirin/Flucelvax. GSK's Fluarix/FluLaval accounts for the third highest share of the influenza vaccines market. FluMist/Fluenz and Afluria/Fluvax stands at the fourth and fifth position in the influenza vaccines market, while Flublok has captured least share of the influenza vaccines market. Complete report available at: http://www.marketreportsonline.com/545524.html

GBI Research, the leading business intelligence provider has released its latest research “Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants” which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2018. View full report with TOC: http://www.reportsandintelligence.com/seasonal-influenza-vaccine-in-asia-pacific-to-2018-positive-impact-of-government-support-offset-by-limited-production-capacity-high-investment-and-strict-regulations-as-barriers-to-new-entrants-market

Influenza Vaccine Market research report delivers a comprehensive study on production capacity, consumption, import and export for all major regions across the world. The report provides is a professional inclusive study on the current state for the market. Analysis and discussion of important industry like market trends, size, share, growth estimates are mentioned in the report.

For much of the 20th century, vaccines were a pharmaceutical success story largely associated with children. Aggressive immunization programs eradicated Polio and Smallpox among developed nations and nearly eliminated Mumps, Pertussis, Measles, and other diseases. While Pediatric Vaccines are an important market, it is now adults who are fueling growth of vaccine products. The world adult vaccines market is expected to nearly double by 2020 from the current figure of 2012.

24 Market Reports provides a complete data analysis of Global Avian Influenza Vaccines Market by Manufacturers, Regions, Type and Application, Forecast to 2021 with Market value, Sales, Price, Industry Analysis and Forecast with the help of Industry Experts. Avian influenza refers to the disease caused by infection with avian (bird) influenza (flu) Type A viruses. These viruses occur naturally among wild aquatic birds worldwide and can infect domestic poultry and other bird and animal species. Avian flu viruses do not normally infect humans. However, sporadic human infections with avian flu viruses have occurred.

The report titled “Global Influenza Drugs and Vaccines Market : Opportunities and Forecast (2016-2021). For more mail info@azothanalytics.com

iGATE Research has released a research report on “Global Influenza Vaccines Market, Persons Vaccinated, Brand Analysis, Size, Share, Growth, Trends, Major Deals - Forecast to 2024” Click here to view the complete report: http://igateresearch.com/FullReportDetail.php?p=128 Contact US iGATE Research PVT LTD Ravi Sinha Sales Manager Marketing and Sales Divison Email: ravi.sinha@igateresearch.com Contact: +91-858-684-0791, +91-821-092-7469 (INDIA) Web: www.igateresearch.com

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine. Complete report available at http://www.marketreportsonline.com/542644.html.

Industry Experts unveiled the new market research report on Influenza. The new global report ‘Global Influenza Market – Vaccines and Therapeutics’ reveals that the market for seasonal influenza vaccines is estimated at 543 million doses valued at US$4.9 billion in 2016 and projected to touch US$714 million doses equated to US$7.9 billion by 2022. In terms of market value, North America is estimated the largest market with US$2.1 billion in 2016 while Europe is projected to be the fastest growing market for Influenza vaccines during the analysis period 2016-2022 with a CAGR of 11.7%. Hyderabad, India based Industry Experts is a multi industry focused business information provider. For more details, please visit http://industry-experts.com/verticals/healthcare-and-pharma/global-influenza-market-vaccines-and-therapeutics

Influenza vaccine market for West Europe was more than US$ 500 Million. United Kingdom is having the highest seasonal influenza vaccine market share followed by Germany and France respectively. In children vaccination, United Kingdom is the leader and France holds the second spot. In adult vaccination United Kingdom and Germany have a close fight for top slot.

Global Influenza Vaccine Market is worth more than US$ 5 Billion. Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period. United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine Market Share was almost 4 times more than China and Japan Influenza Vaccine Market Share. United States & China together captures close to 60 percent in Pediatrics Influenza Vaccine Market Share. Whereas, in adult vaccination segments, United States and Japan will share more than 50 percent market share by 2022.

Europe Influenza Vaccine Market was close to US$ 1 Billion. United Kingdom holds the highest seasonal influenza vaccine market share in Europe. United Kingdom, Germany, France, Italy & Spain together holds more than 80 percent of influenza vaccine market share. In children vaccine market, United Kingdom is the leader and France holds the second spot. In adult vaccine market United Kingdom and Germany have a close fight for top slot. Download Full Report: http://www.renub.com/europe-influenza-vaccine-market-and-forecast-23-countries-market-and-vaccinated-population-data-by-pediatrics-and-adult-and-vaccine-brands-analysis-1077-p.php

Nordics Seasonal Influenza Vaccine Market Forecast in (Denmark, Finland, Iceland, Norway & Sweden) By (Child & Adult) Vaccination report published by Renub Research. According to this report, Sweden is having the highest seasonal influenza vaccine market share. In terms of children vaccination, Sweden & Denmark hold nearly 70 percent market share in 2016 whereas, in adult vaccination segments, these two will share more than 60 percent market share by 2022. Download full Report: http://www.renub.com/nordics-seasonal-influenza-vaccine-market-forecast-in-denmark-finland-iceland-norway-and-sweden-by-child-and-adult-vaccination-1041-p.php

United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024. Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine. Buy Now: http://www.dpiresearch.com/report-details.php?P_ID=109 Long–term Growth Projection and Development: • Sanofi to Acquire Protein Sciences Corporation • It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024 • Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season • It is projected that GSK flu vaccine sales value will reach around US$ 1.5 Billion by 2024 • BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine

Adult Vaccines Market

Global Influenza Vaccine Market is worth more than US$ 5 Billion. Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period. United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine Market Share was almost 4 times more than China and Japan Influenza Vaccine Market Share. United States & China together captures close to 60 percent in Pediatrics Influenza Vaccine Market Share. Whereas, in adult vaccination segments, United States and Japan will share more than 50 percent market share by 2022.

The global animal vaccines market size is expected to reach USD 16.27 billion by 2028 according to a new study by Polaris Market Research.

United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024. Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine. Buy Now: http://www.dpiresearch.com/report-details.php?P_ID=109 Long–term Growth Projection and Development: • Sanofi to Acquire Protein Sciences Corporation • It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024 • Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season • It is projected that GSK flu vaccine sales value will reach around US$ 1.5 Billion by 2024 • BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine

Influenza Vaccine is also known as flu in the shot and is used for guard against influenza virus. An influenza vaccine is a mixture of 3 influenza viruses i.e. type A with H3N2 virus strain, influenza type A with H1N1 virus strain and influenza type B virus strain. Global Influenza Vaccine Market is projected to cross more than US$ 5 Billion. In the recent H1N1 pandemic seems to have brought in a never-before acceptance towards vaccination for flu. The number of adults who took the vaccine raised this year compared to the last year, say vaccine manufacturing companies. For More Information: http://www.renub.com/global-influenza-vaccine-market-is-projected-to-cross-more-than-us-5-billion-57-nd.php The influenza virus has been a concern in infecting millions of people on yearly basis. With the vaccination programs against influenza infections necessitating has to manufacture million doses within a very short span of time.

The 7 major seasonal influenza markets reached a value of US$ 8.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 41.6 Billion by 2034, exhibiting a growth rate (CAGR) of 15.08% during 2024-2034.

Influenza virus is mostly activated in the winter season every year in the European region. Vaccination is the best way to prevent from Influenza virus. It is anticipated that Influenza vaccine market is near to US$ 1 Billion due to a large target population, strong public healthcare infrastructure, high per capita healthcare spending and influenza vaccination program in European countries. Our research report title “Europe Influenza Vaccine Market, Vaccinated Population (23 Countries Market Data) By (Child & Adult) & Forecast” cover the following points: • Influenza vaccinated population • Influenza vaccinated market • Influenza Vaccine Covered (Vaxigrip/Fluzone, Fluarix/ Flulaval, FluMist/Fluenz, Afluria/Fluvax and Fluvirin/Flucelvax, Anflu) • 23 Countries Covered (Netherlands, Denmark, Estonia, Finland, Germany, France, Hungary, Iceland, Ireland, Italy, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom)

Influenza Vaccine Market in Italy, Malta, Portugal and Spain (South Europe) By (Child & Adult) Forecast is report published by Renub Research. According to this report, in the Southern European countries, Italy is having the highest seasonal influenza vaccine market share in South Europe followed by Spain. In terms of children vaccination, Italy & Spain holds more than 80 percent market share whereas, in adult vaccination segments, these two will share more than 90 percent market share by 2022. Download Full Report: http://www.renub.com/influenza-vaccine-market-in-italy-malta-portugal-and-spain-south-europe-by-child-and-adult-forecast-1065-p.php

iGATE RESEARCH report entitled “Global - Adult Vaccines Market & Company Analysis to 2020” is a 232 page report with 142 Figures and 8 Tables. This report studies in detail the adult vaccines market disease wise, company wise sales analysis and strategic alliances, mergers and acquisitions along with growth drivers and hindrances for the vaccines market landscape. Click here to view the complete report: http://www.igateresearch.com/ProductDetail.php?pd_name=Global%20-%20Adult%20Vaccines%20Market%20%20Analysis%20to%202020 Contact US iGATE Research PVT LTD Ravi Sinha Sales Manager Marketing and Sales Divison Email: ravi.sinha@igateresearch.com Contact: +91-858-684-0791, +91-706-527-9335 (INDIA) Web: www.igateresearch.com

For much of the 20th century, vaccines were a pharmaceutical success story largely associated with children. Aggressive immunization programs eradicated Polio and Smallpox among developed nations and nearly eliminated Mumps, Pertussis, Measles, and other diseases. While Pediatric Vaccines are an important market, it is now adults who are fueling growth of vaccine products. The world adult vaccines market is expected to nearly double by 2020 from the current figure of 2012.

Seasonal Influenza Vaccination Market in Lithuania, Estonia, Latvia (Baltic Countries) By (Child & Adult) Forecast report published by Renub Research. According to this report, in the Baltic Countries, Lithuania is having the highest seasonal influenza vaccine market share followed by Latvia and Estonia. In terms of children vaccination, Lithuania & Latvia hold nearly 70 percent market share in 2016 whereas, in adult vaccination segments, these two will share more than 95 percent market share by 2022. Download full Report: http://www.renub.com/seasonal-influenza-vaccination-market-in-lithuania-estonia-latvia-baltic-countries-by-child-and-adult-forecast-1017-p.php

Big Market Research adds a report “Global Human Vaccine Market- Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast 2020" Get Complete Report @ http://www.bigmarketresearch.com/global-human-vaccine-market Human vaccines are of two types: preventable human vaccines and therapeutic human vaccines. Preventable human vaccines are used both for adults and children. Pediatric human vaccines are used to immunize children against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. Enquire about report @ http://www.bigmarketresearch.com/report-enquiry/385329

Dive into the $70.7 billion vaccine market with data-backed insights on growth, trends, and future potential. Explore key segments, market drivers, and challenges in this dynamic healthcare landscape.

Bharat Book presents the report on “Global Markets for Vaccine Technologies” (https://www.bharatbook.com/healthcare-market-research-reports-168817/global-vaccine-technologies.html). This report explores present and future strategies within the vaccine technology market, which is divided into vaccines for both humans and animals.

mRNA Vaccines Market

Vaccine is a preparation of weak or killed pathogen to stimulate the immunity process of the body. The vaccine market is a segment under the pediatric drugs market, which accounts to 80% of the pharmaceutical drugs market. The demand for pediatric vaccines is the major driving force of the market. Get access to detailed report at: https://www.alliedmarketresearch.com/vaccines-market

iGATE RESEARCH report entitled “Global - Adult Vaccines Market & Company Analysis to 2020” is a 232 page report with 142 Figures and 8 Tables. This report studies in detail the adult vaccines market disease wise, company wise sales analysis and strategic alliances, mergers and acquisitions along with growth drivers and hindrances for the vaccines market landscape. Click here to view the complete report: http://www.igateresearch.com/ProductDetail.php?pd_name=Global%20-%20Adult%20Vaccines%20Market%20%20Analysis%20to%202020 Contact US iGATE Research PVT LTD Ravi Sinha Sales Manager Marketing and Sales Divison Email: ravi.sinha@igateresearch.com Contact: +91-858-684-0791, +91-706-527-9335 (INDIA) Web: www.igateresearch.com

Click here to view the complete report: http://www.igateresearch.com/ProductDetail.php?pd_name=Global%20-%20Adult%20Vaccines%20Market%20%20Analysis%20to%202020 Contact US iGATE Research PVT LTD Ravi Sinha Sales Manager Marketing and Sales Divison Email: ravi.sinha@igateresearch.com Contact: +91-858-684-0791, +91-706-527-9335 (INDIA) Web: www.igateresearch.com

Rising concern about preventing and curing of chronic diseases such as diabetes, cholera, influenza and polio are anticipated to drive the global vaccine market over the forecast period.

Big Market Research : Japanese Microbiology Testing Market : Trends, Size, Supplier Shares and Country Forecasts 2014 To Get More Details @ http://www.bigmarketresearch.com/future-horizons-and-growth-strategies-in-the-japanese-microbiology-testing-2014-supplier-shares-and-country-forecasts-market This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies.

Veterinary Vaccines Market 2020 Analysis and Review of Veterinary Vaccines Market by Product - Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, and Recombinant Vaccines for 2020-2030

China was about 1.45 billion, and that of broilers was approximate to 10 billion. The output volume of eggs in China was 28.61 million tons in 2012, increasing by 1.76% YOY. According to National Compulsory Immunization Plan of Animal Epidemic Diseases 2013 issued by Ministry of Agriculture of China, the government conducts compulsory immunizations against 4 diseases, including highly pathogenic avian influenza. The government is responsible for appropriations. In 2012, the scale of China avian influenza vaccine market was over CNY 1 billion.

Veterinary Vaccines Market: Greater Adoption of Live Attenuated Vaccines Likely to be Witnessed Throughout the Forecast Period: Middle East Industry Analysis & Opportunity Assessment, 2016 - 2026

The vaccine market is likely to witness a significant growth throughout the forecast period due to the growing prevalence of diseases, increasing government and non-government funding for vaccine development & distribution and increasing investments by companies to develop new vaccines. Furthermore, growing demand for preventive vaccines, rising consciousness about vaccination coupled with mounting demand from the emerging countries is expected to boost the global vaccine businesses in the near future.

Porcine vaccines aid the swine or hogs suffering from epidemic swine diseases. It also helps in improving overall efficiency in protecting swine from deadly viruses, bacteria and increases the production level of high-quality meat and gelatine

GBI Research found that the adult and adolescent vaccines market in the top seven markets was valued at $7.2 billion in 2011, increasing at a Compound Annual Growth Rate (CAGR) of 6.9% during the 2007-2011 historic period. The market is projected to witness a growth of 5.6% during the 2011-2018 forecast period to reach $10.5 billion. The growth in the adult and adolescent vaccines market is driven by increased uptake of pneumococcal vaccines such as Prevnar 13 which got approved for use in people aged 50 and older. The pneumococcal vaccines market is expected to grow at a CAGR of 19% during the forecast period and reach $1.7 billion in 2018, from $0.5 billion in 2011. View full report with TOC: http://www.reportsandintelligence.com/adult-and-adolescent-vaccines-to-2018-promising-novel-candidates-in-late-stage-development-and-prevnar-approval-for-use-in-adults-to-drive-growth-market

Seasonal Influenza Vaccination Market in Lithuania, Estonia, Latvia (Baltic Countries) By (Child & Adult) Forecast report published by Renub Research. According to this report, in the Baltic Countries, Lithuania is having the highest seasonal influenza vaccine market share followed by Latvia and Estonia. In terms of children vaccination, Lithuania & Latvia hold nearly 70 percent market share in 2016 whereas, in adult vaccination segments, these two will share more than 95 percent market share by 2022. Download full Report: http://www.renub.com/seasonal-influenza-vaccination-market-in-lithuania-estonia-latvia-baltic-countries-by-child-and-adult-forecast-1017-p.php

Seasonal Influenza Vaccination Market in Lithuania, Estonia, Latvia (Baltic Countries) By (Child & Adult) Forecast report published by Renub Research. According to this report, in the Baltic Countries, Lithuania is having the highest seasonal influenza vaccine market share followed by Latvia and Estonia. In terms of children vaccination, Lithuania & Latvia hold nearly 70 percent market share in 2016 whereas, in adult vaccination segments, these two will share more than 95 percent market share by 2022.

United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024. Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine. Buy Now: http://www.dpiresearch.com/report-details.php?P_ID=109 Long–term Growth Projection and Development: • Sanofi to Acquire Protein Sciences Corporation • It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024 • Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season • It is projected that GSK flu vaccine sales value will reach around US$ 1.5 Billion by 2024 • BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine